Tocilizumab biosimilar (Bio-Thera Solutions)

托珠单抗生物类似药（百奥泰生物）

Report date: 2024/08/14 17:09:38

Base Information

Drug NameTocilizumab biosimilar (Bio-Thera Solutions)
Drug Alias NameTocilizumab-bavi托珠单抗生物仿制药（百奥泰生物）重组人源化抗人白介素6受体单抗（百奥泰生物）施瑞立TOFIDENCE +[7] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-6 receptor alpha subunit antagonistsInterleukin-6 receptor subunit beta antagonists
TargetsInterleukin-6 receptor alpha subunitInterleukin-6 receptor subunit beta
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Polyarticular Juvenile Idiopathic ArthritisCytokine Release Syndrome +[5] 
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)Polyarticular Juvenile Idiopathic ArthritisCytokine Release Syndrome +[5] 
Approved Indications in ChinaCytokine Release SyndromeArthritis, RheumatoidArthritis, Juvenile
Original Approved Country/TerritoryMainland China
Original Approved Date2023/01/16
Country/TerritoryBulgariaUnited StatesUkraine +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBio-Thera Solutions Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOrganonBiogen Netherlands BvBio-Thera Solutions Ltd +[5] 
Inactive CompaniesBiogen Inc
Active IndicationsCoronavirus Disease 2019 (COVID-19)Polyarticular Juvenile Idiopathic ArthritisCytokine Release Syndrome +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AC07
Related LinksN/A